Patrick Alexander Ott MD

PubMed

• 1 citations
  A multi-adjuvant personal neoantigen vaccine generates potent immunity in melanoma.
  Eryn Blass, Derin B Keskin, Chloe R Tu, Cleo Forman, Allison Vanasse
  Cell. 2025-07-09
• 3 citations
  First-in-Human Clinical Trial of Vaccination with WDVAX, a Dendritic Cell-Activating Scaffold Incorporating Autologous Tumor Cell Lysate, in Patients with Metastatic M...
  F Stephen Hodi, Anita Giobbie-Hurder, Kwasi Adu-Berchie, Srin Ranasinghe, Ana Lako
  Cancer Immunology Research. 2025-07-02
• Immunotherapy Rechallenge Is Effective for Most Patients With Late Progression After Initial Ipilimumab + Nivolumab Response.
  Ethan Trim, Anita Giobbie-Hurder, Tamara A Sussman, David Liu, Megan Insco
  Pigment Cell & Melanoma Research. 2025-07-01

Journal Articles

• Pan-Tumor Genomic Biomarkers for PD-1 Checkpoint Blockade–Based Immunotherapy  
  Jonathan Cheng, Patrick A Ott, Elizabeth R Plimack, Antoni Ribas, Andrew Joe, Science Magazine
• Pembrolizumab for Advanced Prostate Adenocarcinoma: Findings of the KEYNOTE-028 Study  
  M Gould, P Yang, P A Ott, Annals of Oncology
• A Cloning and Expression System to Probe T Cell Receptor Specificity and Assess Functional Avidity to Neoantigens  
  William J Lane, Patrick A Ott, Catherine J Wu, Donna E Leet, Blood

Lectures

• Personalized Neoantigen Vaccine 
  ASCO Annual Meeting 2019 - Chicago, IL - 5/3/2019
• Overview of Immune-Related Toxicities 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/5/2018